Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe Mounjaro KwikPen uses a needle that is 4 mm long and 32 gauge. That short, fine tip is intentional: it is designed for subcutaneous injection just beneath the skin's surface, not into muscle. Most people find it noticeably smaller than they expected. Because tirzepatide is a prescription-only medicine requiring a clinical assessment before it can be dispensed, you would never choose the needle yourself — that is all handled through the pen's design and your prescriber's guidance.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Open a Mounjaro KwikPen for the first time and the needle is completely hidden, sealed inside a grey inner cap that sits beneath the outer cap. That surprises a lot of people who have worked themselves up imagining something far more imposing. The needle attached to the Mounjaro pen is 4 mm long and 32 gauge, which puts it at the shorter, finer end of the range used in any self-administered injectable medicine. A standard blood-test needle, by comparison, is typically longer and wider.
The 32-gauge measurement refers to the outer diameter of the needle shaft. Higher gauge numbers mean thinner needles. At 32 gauge, the tip creates minimal resistance and causes very little sensation for most people. If you want to understand exactly how the Mounjaro injection needle is constructed and why its dimensions are chosen for subcutaneous use, that detail is covered in full on the linked page. That is exactly as far as it needs to go to reach subcutaneous tissue (the layer of fat that sits just under the skin) where tirzepatide is absorbed reliably.
There is a common worry, particularly among people who have only ever had vaccines or blood draws, that self-injection means something clinical and uncomfortable. The reality with a 4 mm needle is typically quite different. Our prescribers hear this most weeks from people starting treatment, and nearly all of them report the injection itself as the least difficult part of the routine.
Because the needle is only 4 mm, Mounjaro can be injected into three sites without any special technique adjustment for most adults: the abdomen (at least 5 cm from the navel), the outer thigh, or the upper arm. The NHS guidance on Mounjaro injection technique recommends rotating between sites and between spots within each site to avoid building up localised reactions over time.
At 4 mm you do not need to pinch the skin before injecting unless your prescriber advises otherwise, this distinguishes shorter pen needles from older, longer designs where pinching helped avoid inadvertent intramuscular injection. Simply clean the site, let it dry, press the pen firmly and flat against the skin, and activate. The needle's brief contact with the skin is why proper pressure matters: a firm, flat press ensures the full 4 mm reaches the tissue rather than compressing without penetrating.
Rotating sites is not optional good practice; it is a meaningful part of keeping the injection effective and comfortable over the months you are on treatment. Lipohypertrophy (a lumpiness that develops when the same small patch of skin is used repeatedly) can slow absorption. The dimensions of the Mounjaro needle mean any of the three sites works equally well, so there is no reason to favour one persistently.
Each KwikPen holds four weekly doses. You do not remove and reattach needles between uses, the pen's integrated needle design stays in place for the pen's lifetime. What you must do after each dose is replace the outer cap and store the pen correctly until the following week. Never reuse a needle between separate pens or pass a pen to another person.
When the pen is empty, it needs to go into a sharps bin rather than general household waste. A 1-litre sharps container is the standard size for home use and takes several spent pens comfortably. Most GP practices and some pharmacies will accept sealed sharps bins for disposal, check locally. This is worth arranging before you start treatment rather than having a full bin and nowhere to put it.
For the full detail on storage windows and the exact steps for attaching the cap before and after use, the Mounjaro SmPC on the Electronic Medicines Compendium is the definitive reference. It is the source your prescriber follows too.
No. The needle dimensions are the same across the 2.5 mg starter pen and every strength up to 15 mg. What changes between pens is the volume and concentration of the medicine, not the delivery mechanism. This matters because some people starting titration wonder whether their technique needs to change as doses increase. It does not, the same site, the same firm press, the same 4 mm depth applies throughout your treatment journey.
If you are transferring from another injectable medicine and find the needle feels different in handling, that is usually down to pen ergonomics rather than needle size. There is detailed guidance on attaching the Mounjaro pen needle correctly that covers the exact steps. The NHS tirzepatide patient information also walks through injection preparation, and it is worth reading alongside your Patient Information Leaflet before your first dose. The NHS tirzepatide medicines page is a good plain-English starting point.
If you have questions about whether Mounjaro is the right treatment for your situation, a free consultation with a GPhC-registered prescriber is the natural next step. You can start your free consultation here.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.